Plasma copeptin and the risk of diabetes mellitus

Circulation

Volumn 121, Issue 19, 2010, Pages 2102-2108

  Enhörning, Sofia ^a,b   Wang, Thomas J ^c,e   Nilsson, Peter M ^a,b   Almgren, Peter ^a   Hedblad, Bo ^a   Berglund, Göran ^a   Struck, Joachim ^g   Morgenthaler, Nils G ^g   Bergmann, Andreas ^g   Lindholm, Eero ^a   Groop, Leif ^a   Lyssenko, Valeria ^a   Orho Melander, Marju ^a   Newton Cheh, Christopher ^c,d,e,f   Melander, Olle ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Division of Cardiology   (United States)

^d Center for Human Genetic Research   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g THERMO FISHER SCIENTIFIC   (Germany)

Author keywords

Arginine vasopressin; Copeptin; Diabetes mellitus; Epidemiology; Risk factors

Indexed keywords

ARGIPRESSIN DERIVATIVE; C REACTIVE PROTEIN; COPEPTIN; CYSTATIN C; UNCLASSIFIED DRUG;

ADULT; ANTHROPOMETRY; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLUCOSE METABOLISM; HUMAN; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLYCOPEPTIDES; HUMANS; INSULIN; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; SWEDEN;

EID: 77953124970     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.909663     Document Type: Article

References (37)

1. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T, Merki R, Schaub N, Bingisser R, Christ M, Mueller C. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009;54:60-68.
2. Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009;30:1187-1194.
3. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, Kullo IJ. Plasma carboxy-terminal pro-vasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. J Clin Endo-crinol Metab. 2009;94:2558-2564.
4. Morel A, O'Carroll AM, Brownstein MJ, Lolait SJ. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature. 1992; 356:523-526.
5. Folny V, Raufaste D, Lukovic L, Pouzet B, Rochard P, Pascal M, Serradeil-Le Gal C. Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas. Am J Physiol Endocrinol Metab. 2003;285:E566-E576.
6. de Keyzer Y, Auzan C, Lenne F, Beldjord C, Thibonnier M, Bertagna X, Clauser E. Cloning and characterization of the human V3 pituitary vaso-pressin receptor. FEBS Lett. 1994;356:215-220.
7. Lolait SJ, O'Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ. Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature. 1992;357:336-339.
8. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099-2112.
9. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297:1332-1343.
10. Filep J, Rosenkranz B. Mechanism of vasopressin-induced platelet aggregation. Thromb Res. 1987;45:7-15.
11. Ohlstein EH, Berkowitz BA. Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists. J Pharmacol Exp Ther. 1986;239:737-741.
12. Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med. 2007;39:346-358.
13. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, Friesenecker B, Hasibeder WR. Arginine vasopressin in advanced vaso-dilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107:2313-2319.
14. Keppens S, de Wulf H. The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis. Biochim Biophys Acta. 1979;588: 63-69.
15. Abu-Basha EA, Yibchok-Anun S, Hsu WH. Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism. 2002;51:1184-1190.
16. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1: receptor physiology. Crit Care. 2003;7: 427-434.
17. Rabadan-Diehl C, Aguilera G. Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology. 1998;139:3220-3226.
18. Zerbe RL, Vinicor F, Robertson GL. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes. 1979;28:503-508.
19. Spruce BA, McCulloch AJ, Burd J, Orskov H, Heaton A, Baylis PH, Alberti KG. The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol. 1985;22:463-468.
20. Aoyagi T, Birumachi J, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J, Tanoue A. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007;148:2075-2084.
21. Fujiwara Y, Hiroyama M, Sanbe A, Aoyagi T, Birumachi J, Yamauchi J, Tsujimoto G, Tanoue A. Insulin hypersensitivity in mice lacking the V1b vasopressin receptor. J Physiol. 2007;584:235-244.
22. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005;26:2500-2504.
23. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study: design and feasibility. J Intern Med. 1993;233:45-51.
24. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arte-rioscler Thromb Vasc Biol. 2007;27:1411-1416.
25. Engstrom G, Hedblad B, Nilsson P, Wollmer P, Berglund G, Janzon L. Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. J Intern Med. 2003;253:574-581.
26. Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009;94:123-129.
27. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442-443.
28. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S. Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care. 2008;31:2038-2043.
29. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD. Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol. 2001;17:983-989.
30. Nilsson PM, Engstrom G, Hedblad B, Frystyk J, Persson MM, Berglund G, Flyvbjerg A. Plasma adiponectin levels in relation to carotid intima media thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol. 2006;26:2758-2762.
31. Wilson PW, Meigs JB, Sullivan L, Fox CS, Nathan DM, D'Agostino RB Sr. Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med. 2007;167:1068-1074.
32. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172.
33. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15:815-819.
34. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004;23:2109-2123.
35. Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48:204-213.
36. Ohlson LO, Larsson B, Bjorntorp P, Eriksson H, Svardsudd K, Welin L, Tibblin G, Wilhelmsen L. Risk factors for type 2 (non-insulin-dependent) diabetes mellitus: thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia. 1988;31:798-805.
37. Manjer J, Carlsson S, Elmstahl S, Gullberg B, Janzon L, Lindstrom M, Mattisson I, Berglund G. The Malmo Diet and Cancer Study: repre-sentativity, cancer incidence and mortality in participants and non-participants. Eur J Cancer Prev. 2001;10:489-499.